University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Michelle Melisko, M.D.

Breast cancer specialist

Dr. Michelle E. Melisko is a cancer specialist with expertise in breast cancer treatment and research. She is interested in testing new chemotherapy combinations, biological therapies and immunotherapies for breast cancer, with a particular focus on treatment of cancer that has spread to the brain. She also hopes to educate patients and encourage their participation in clinical trials to make more rapid advances in breast cancer treatment.

Melisko earned a medical degree at the Wake Forest University School of Medicine and completed a residency in internal medicine at Stanford Hospital and Clinics and a fellowship in hematology and oncology at UCSF Medical Center.

Clinics

Carol Franc Buck Breast Care Center
1600 Divisadero St., Second Floor
San Francisco, CA 94115
Phone: (415) 353-7070
Surgery Fax: (415) 353-7050
Oncology Fax: (415) 353-7692

Hours: Monday to Friday
8 a.m. – 5 p.m.

Cancer Risk Program
1600 Divisadero St., Second Floor
San Francisco, CA 94143-1714
Phone: (415) 885-7779
Fax: (415) 885-3787

Hours: Monday to Friday
9 a.m. – 5 p.m.

Conditions & Treatments

More about Michelle Melisko

Education

Wake Forest University School of Medicine 1997

Residencies

Stanford Hospital and Clinics, Internal Medicine 2000

Fellowships

UCSF Medical Center, Hematology/Oncology 2003

Selected Research and Publications

  1. Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Raza M, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian N, Freedman-Cass D. Survivorship: fatigue, version 1.2014. J Natl Compr Canc Netw. 2014 Jun; 12(6):876-87.
  2. Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Raza M, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian N, Freedman-Cass D. Survivorship: sleep disorders, version 1.2014. J Natl Compr Canc Netw. 2014 May 1; 12(5):630-42.
  3. Chien AJ, Munster PN, Melisko ME, Rugo HS, Park JW, Goga A, Auerback G, Khanafshar E, Ordovas K, Koch KM, Moasser MM. Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. J Clin Oncol. 2014 May 10; 32(14):1472-9.
  4. Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Raza M, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian N, Freedman-Cass D. Survivorship: pain version 1.2014. J Natl Compr Canc Netw. 2014 Apr 1; 12(4):488-500.
  5. Denlinger CS, Carlson RW, Are M, Baker KS, Davis E, Edge SB, Friedman DL, Goldman M, Jones L, King A, Kvale E, Langbaum TS, Ligibel JA, McCabe MS, McVary KT, Melisko M, Montoya JG, Mooney K, Morgan MA, O'Connor T, Paskett ED, Raza M, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian N, Freedman-Cass D. Survivorship: sexual dysfunction (male), version 1.2013. J Natl Compr Canc Netw. 2014 Mar 1; 12(3):356-63.
  6. Denlinger CS, Carlson RW, Are M, Baker KS, Davis E, Edge SB, Friedman DL, Goldman M, Jones L, King A, Kvale E, Langbaum TS, Ligibel JA, McCabe MS, McVary KT, Melisko M, Montoya JG, Mooney K, Morgan MA, O'Connor T, Paskett ED, Raza M, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian N, Freedman-Cass D. Survivorship: sexual dysfunction (female), version 1.2013. J Natl Compr Canc Netw. 2014 Feb 1; 12(2):184-92.
  7. Denlinger CS, Carlson RW, Are M, Baker KS, Davis E, Edge SB, Friedman DL, Goldman M, Jones L, King A, Kvale E, Langbaum TS, Ligibel JA, McCabe MS, McVary KT, Melisko M, Montoya JG, Mooney K, Morgan MA, O'Connor T, Paskett ED, Raza M, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian N, Freedman-Cass D. Survivorship: introduction and definition. J Natl Compr Canc Netw. 2014 Jan 1; 12(1):34-45.
  8. Merriman JD, Aouizerat BE, Cataldo JK, Dunn L, Cooper BA, West C, Paul SM, Baggott CR, Dhruva A, Kober K, Langford DJ, Leutwyler H, Ritchie CS, Abrams G, Dodd M, Elboim C, Hamolsky D, Melisko M, Miaskowski C. Association between an interleukin 1 receptor, type I promoter polymorphism and self-reported attentional function in women with breast cancer. Cytokine. 2014 Feb; 65(2):192-201.
  9. Magbanua MJ, Melisko M, Roy R, Sosa EV, Hauranieh L, Kablanian A, Eisenbud LE, Ryazantsev A, Au A, Scott JH, Park JW. Molecular profiling of tumor cells in cerebrospinal fluid and matched primary tumors from metastatic breast cancer patients with leptomeningeal carcinomatosis. Cancer Res. 2013 Dec 1; 73(23):7134-43.
  10. Rugo HS, Campone M, Amadori D, Aldrighetti D, Conte P, Wardley A, Villanueva C, Melisko M, McHenry MB, Liu D, Lee F, Pivot X. A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer. Breast Cancer Res Treat. 2013 Jun; 139(2):411-9.
  11. Hahn EE, Ganz PA, Melisko ME, Pierce JP, von Friederichs-Fitzwater M, Lane KT, Hiatt RA. Provider perceptions and expectations of breast cancer posttreatment care: a University of California Athena Breast Health Network project. J Cancer Surviv. 2013 Sep; 7(3):323-30.
  12. Wheelock A, Mihalis E, Hamolsky D, Ernest ML, Lopez NS, Hwang J, Melisko M. Survivorship clinic group educational sessions: adoption, acceptance, and attendance. J Cancer Educ. 2013 Mar; 28(1):79-83.
  13. Kaplan CP, Nápoles AM, Dohan D, Shelley Hwang E, Melisko M, Nickleach D, Quinn JA, Haas J. Clinical trial discussion, referral, and recruitment: physician, patient, and system factors. Cancer Causes Control. 2013 May; 24(5):979-88.
  14. Van Onselen C, Aouizerat BE, Dunn LB, Paul SM, West C, Hamolsky D, Lee K, Melisko M, Neuhaus J, Miaskowski C. Differences in sleep disturbance, fatigue and energy levels between women with and without breast pain prior to breast cancer surgery. Breast. 2013 Jun; 22(3):273-6.
  15. Bock M, Moore D, Hwang J, Shumay D, Lawson L, Hamolsky D, Esserman L, Rugo H, Chien AJ, Park J, Munster P, Melisko M. The impact of an electronic health questionnaire on symptom management and behavior reporting for breast cancer survivors. Breast Cancer Res Treat. 2012 Aug; 134(3):1327-35.
  16. Niemasik EE, Letourneau J, Dohan D, Katz A, Melisko M, Rugo H, Rosen M. Patient perceptions of reproductive health counseling at the time of cancer diagnosis: a qualitative study of female California cancer survivors. J Cancer Surviv. 2012 Sep; 6(3):324-32.
  17. Lorizio W, Rugo H, Beattie MS, Tchu S, Melese T, Melisko M, Wu AH, Lawrence HJ, Nikoloff M, Ziv E. Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment. Genome Med. 2011; 3(10):64.
  18. Letourneau JM, Ebbel EE, Katz PP, Katz A, Ai WZ, Chien AJ, Melisko ME, Cedars MI, Rosen MP. Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer. 2012 Mar 15; 118(6):1710-7.
  19. Letourneau JM, Ebbel EE, Katz PP, Oktay KH, McCulloch CE, Ai WZ, Chien AJ, Melisko ME, Cedars MI, Rosen MP. Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for cancer. Cancer. 2012 Apr 1; 118(7):1933-9.
  20. Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 2011 Jun 7; 104(12):1828-35.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.